Jean-NoÃ«l Talbot

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11400828/publications.pdf

Version: 2024-02-01

58 papers	2,229 citations	331538 21 h-index	223716 46 g-index
66 all docs	66 docs citations	66 times ranked	2219 citing authors

#	Article	IF	Citations
1	Detection of Hepatocellular Carcinoma with PET/CT: A Prospective Comparison of¹⁸F-Fluorocholine and¹⁸F-FDG in Patients with Cirrhosis or Chronic Liver Disease. Journal of Nuclear Medicine, 2010, 51, 1699-1706.	2.8	183
2	A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism. Medicine (United States), 2015, 94, e1701.	0.4	145
3	Is 18F-Fluorocholine-Positron Emission Tomography/Computerized Tomography a New Imaging Tool for Detecting Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4531-4536.	1.8	132
4	Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. International Journal of Radiation Oncology Biology Physics, 2005, 63, 340-345.	0.4	128
5	PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1285-1289.	3.3	128
6	CT and 18F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1249-1257.	0.4	127
7	Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in nonâ€“small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1432-1441.	0.4	117
8	The EANM practice guidelines for parathyroid imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2801-2822.	3.3	116
9	18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 943-966.	3.3	101
10	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncology, The, 2018, 19, e534-e545.	5.1	98
11	Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?. Journal of Nuclear Medicine, 2006, 47, 1455-62.	2.8	90
12	18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1995-2004.	3.3	67
13	Impact of Fluorodihydroxyphenylalanine-(18F) Positron Emission Tomography on Management of Adult Patients with Documented or Occult Digestive Endocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1295-1301.	1.8	65
14	Usefulness of combination of high-resolution ultrasonography and dual-phase dual-isotope iodine 123/technetium Tc 99m sestamibi scintigraphy for the preoperative localization of hyperplastic parathyroid glands in renal hyperparathyroidism. American Journal of Kidney Diseases, 2005, 45, 344-352.	2.1	60
15	Novel DOTA-Neurotensin Analogues for111In Scintigraphy and68Ga PET Imaging of Neurotensin Receptor-Positive Tumors. Bioconjugate Chemistry, 2011, 22, 1374-1385.	1.8	48
16	Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nuclear Medicine Communications, 2010, 31, 389-397.	0.5	45
17	Incidental uptake of ¹⁸F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radiology and Oncology, 2014, 48, 228-234.	0.6	44
18	Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nuclear Medicine Communications, 2012, 33, 775-779.	0.5	41

#	Article	IF	Citations
19	68Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patientsâ€™ disease management and adequacy of impact. Scientific Reports, 2020, 10, 2104.	1.6	33
20	Diffusely Increased F-18 FDG Uptake in Bone Marrow in a Patient With Acute Anemia and Recent Erythropoietin Therapy. Clinical Nuclear Medicine, 2003, 28, 771-772.	0.7	30
21	¹⁸Fâ€fluorocholine PET/CT in MEN1ÂPatients with Primary Hyperparathyroidism. World Journal of Surgery, 2020, 44, 3761-3769.	0.8	25
22	A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nuclear Medicine Communications, 2012, 33, 757-765.	0.5	22
23	Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography. Gastroenterology, 2019, 157, 807-822.	0.6	22
24	Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 396-405.	3.3	20
25	18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study. PLoS ONE, 2018, 13, e0191487.	1.1	18
26	Preclinical Evaluation of 68Ga-DOTA-NT-20.3: A Promising PET Imaging Probe To Discriminate Human Pancreatic Ductal Adenocarcinoma from Pancreatitis. Molecular Pharmaceutics, 2019, 16, 2776-2784.	2.3	18
27	18F-Choline PET/CT for Initial Staging of Advanced Prostate Cancer. American Journal of Roentgenology, 2006, 187, W618-W621.	1.0	18
28	Use of choline PET for studying hepatocellular carcinoma. Clinical and Translational Imaging, 2014, 2, 103-113.	1.1	17
29	A Method to Improve the Semiquantification of 18F-FDG Uptake: Reliability of the Estimated Lean Body Mass Using the Conventional, Low-Dose CT from PET/CT. Journal of Nuclear Medicine, 2016, 57, 753-758.	2.8	14
30	Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2935-2950.	3.3	14
31	A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models. Nuclear Medicine and Biology, 2020, 84-85, 88-95.	0.3	13
32	Fluorodeoxyglucose Imaging Using a Coincidence Gamma Camera to Detect Head and Neck Squamous Cell Carcinoma and Response to Chemotherapy. Annals of Otology, Rhinology and Laryngology, 2002, 111, 763-771.	0.6	12
33	Comparison and evaluation of two RGD peptides labelled with 68Ga or 18F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma. Oncotarget, 2018, 9, 19307-19316.	0.8	12
34	FDOPA-(18F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union. Brazilian Archives of Biology and Technology, 2007, 50, 77-90.	0.5	10
35	Whole-Body 18F-Fluorocholine (FCH) PET/CT and MRI of the Spine for Monitoring Patients With Castration-Resistant Prostate Cancer Metastatic to Bone. Clinical Nuclear Medicine, 2014, 39, 951-959.	0.7	10
36	Equivalent Dose Rate 1 Meter from Neuroendocrine Tumor Patients Exiting the Nuclear Medicine Department After Undergoing Imaging. Journal of Nuclear Medicine, 2017, 58, 1230-1235.	2.8	10

#	Article	IF	Citations
37	Vertebral metastases from neuroendocrine tumours: How to avoid false positives on 68Ga-DOTA-TOC PET using CT pattern analysis?. European Radiology, 2018, 28, 3943-3952.	2.3	10
38	[68Ga]RGD Versus [18F]FDG PET Imaging in Monitoring Treatment Response of a Mouse Model of Human Glioblastoma Tumor with Bevacizumab and/or Temozolomide. Molecular Imaging and Biology, 2019, 21, 297-305.	1.3	10
39	18F-Fluorocholine PET/CT Imaging of Brown Tumors in a Patient With Severe Primary Hyperparathyroidism. Clinical Nuclear Medicine, 2019, 44, 971-974.	0.7	10
40	Impact of sodium 18F-fluoride PET/CT, 18F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study. World Journal of Urology, 2019, 37, 1587-1595.	1.2	10
41	68Ga-DOTATOC PET/CT in detecting neuroendocrine tumours responsible for initial or recurrent paraneoplastic Cushingâ€™s syndrome. Endocrine, 2020, 67, 708-717.	1.1	10
42	Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France. BMC Medical Imaging, 2020, 20, 25.	1.4	10
43	68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models. Anticancer Research, 2016, 36, 4459-4466.	0.5	10
44	Improvement of semi-quantitative small-animal PET data with recovery coefficients: A phantom and rat study. Nuclear Medicine Communications, 2007, 28, 813-822.	0.5	9
45	Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey. Radiology and Oncology, 2014, 48, 20-28.	0.6	8
46	Use of a Coincidence Gamma Camera to Detect Primary Tumor with 18Fluoro-2-Deoxy-Glucose in Cervical Lymph Node Metastases from an Unknown Origin. Annals of Otology, Rhinology and Laryngology, 2000, 109, 755-760.	0.6	7
47	Tumor Heterogeneity Detected by 68Ga DOTATOC and 18F-FDG PET/CTs in One Malignant Insulinoma With Involvement of the Portal Splenic Confluence and Ovarian Metastases. Clinical Nuclear Medicine, 2016, 41, 874-876.	0.7	7
48	Incidental Metastatic Melanoma Identified on 18F-FDOPA PET/CT With Confirmation by Histology. Clinical Nuclear Medicine, 2020, 45, 817-818.	0.7	6
49	Detection of recurrent colorectal carcinoma by 18F-FDG: comparison of the clinical performances of FDG PET and FDG CDET. Nuclear Medicine Communications, 2004, 25, 105-113.	0.5	5
50	An essential practice summary of the new EANM guidelines for parathyroid imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 66, .	0.4	5
51	Patient external dose rate after 177Lu-DOTATATE therapy: factors affecting its decrease and predictive value. International Journal of Medical Sciences, 2021, 18, 2725-2735.	1.1	4
52	Multiple endocrine neoplasia type 1 or 4: detection of hyperfunctioning parathyroid glands with 18F-fluorocholine PET/CT, illustrative cases and pitfalls. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, , .	0.4	3
53	Current evaluation of the clinical utility of Fluoromethylcholine-(18F) PET/CT in Prostate Cancer. Brazilian Archives of Biology and Technology, 2008, 51, 71-75.	0.5	1
54	Strengths and limitations of using18fluorine-fluorodihydroxyphenylalanine PET/CT for congenital hyperinsulinism. Expert Review of Endocrinology and Metabolism, 2014, 9, 477-485.	1.2	1

#	Article	IF	Citations
55	Reply. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 172-172.	3.3	0
56	Editorial Comment: Advances in MRI and PET of the prostate: concurrence or complementarity?. European Radiology, 2018, 28, 3138-3140.	2.3	0
57	Application diagnostique de la tomographie par Ã©mission de positons en France. De la gamma-camÃ©ra modifiÃ©e Ã la machine hybride TEP/TDM.. Bulletin De L'Academie Nationale De Medecine, 2010, 194, 1559-1579.	0.0	0
58	Rare Extramedullary Cardiac Involvement of Recurrent Multiple Myeloma Suspected on 18F-FDG and Confirmed on 18F-Fluorocholine. Clinical Nuclear Medicine, 2020, 45, 916-918.	0.7	0